Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved gefitinib monotherapy for reimbursement for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK.
This is written in the approval document as:
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK
Citation
Gefitinib Monotherapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 22/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/220-gefitinib-monotherapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | EGFR oncogenic variants | Non-Small Cell Lung Cancer | Gefitinib |